Children with amblyopia have increased risk of serious diseases as adults

News
Article

Investigators emphasised that the data does not indicate a causal relationship between the eye disorder and systemic diseases

A young girl with glasses and a patch over one eye to correct amblyopia. Image credit: ©sasha1806 – stock.adobe.com

The findings showed that participants with childhood amblyopia had 29% higher odds of developing diabetes. Image credit: ©sasha1806 – stock.adobe.com

British investigators from University College London (UCL) reported that children with amblyopia have a higher likelihood of developing hypertension, obesity, metabolic syndrome and myocardial infarction in adulthood.1

First author Emily Upton, PhD, and colleagues announced this correlation between amblyopia and compromised health in a press release and emphasised that this does not indicate a causal relationship between the eye disorder and the systemic diseases.

Data analysis

The study included data obtained from over 126,000 individuals in the UK Biobank cohort.The participants ranged in age from 40 to 69 years and all had had an ocular examination.

As part of the recruitment process, the participants were questioned about diagnosis and treatment of amblyopia as children, the persistence of amblyopia into adulthood, and the diagnoses of diabetes, high blood pressure or cardio/cerebrovascular disease.

The investigators also measured the participants’ body mass indices and blood glucose and cholesterol values and tracked patient mortality.

The results showed that a high percentage, 82.2%, of the 3,238 participants who had had amblyopia during children had “persistent reduced vision in 1 eyes as an adult.”

The authors also reported, “The findings showed that participants with amblyopia as a child had 29% higher odds of developing diabetes, 25% higher odds of having hypertension, and 16% higher odds of having obesity. They were also at increased risk of heart attack, even when other risk factors for these conditions, eg, other disease, ethnicity, and social class, were taken into account.”

They also reported a less strong correlation, ie, that the risk of cardiac issues increased in individuals with persistent visual problems as well to some extent in those who had amblyopia in childhood and 20/20 vision in adulthood.

Professor and corresponding author Jugnoo Rahi from UCL Great Ormond Street Institute for Child Health, UCL Institute of Ophthalmology, and Great Ormond Street Hospital, commented on this red flag in childhood, “It is rare to have a ‘marker’ in childhood that is associated with increased risk of serious disease in adult life, and also one that is measured and known for every child – because of population screening.”

Reference

1. Upton E, Doogan C, Fleming V, et al. Associations between unilateral amblyopia in childhood and cardiometabolic disorders in adult life: a cross-sectional and longitudinal analysis of the UK Biobank. 2024; eClinicalMedicine;10.1016/j.eclinm.2024.102493
Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.